Architectural Cases

He Jiankui, widely known as China's "Dr. Frankenstein" for his groundbreaking work on genetically modified infants, faced severe repercussions, including a three-year prison sentence for deceiving medical authorities. Nevertheless, this 41-year-old researcher has not faded into obscurity. Instead, he lives and speaks freely from his residence in a government-supported research hub near Beijing, openly defending his endeavors and asserting that his home country is ready to embrace his innovative vision.

Although restricted from international travel due to passport confiscation, He Jiankui continues to be a vocal, albeit polarizing, presence in China's burgeoning biotech sector. His continued visibility, neither entirely silenced nor fully rehabilitated, prompts observers to question the motivations behind China's seemingly lenient stance. Benjamin Hurlbut, an associate professor at the University of Arizona who has followed He Jiankui's career, notes the paradoxical situation: a state known for its strict censorship appears to be granting him unusual freedom.

Hurlbut suggests that in a climate of escalating Sino-Western tensions and China's rapid technological advancements, He Jiankui might be perceived not as a liability but as a valuable asset. During an interview conducted in his spacious apartment—provided, along with security, by an undisclosed financial backer—the geneticist articulated a growing demand for scientists who are prepared to challenge established norms and push the boundaries of scientific exploration.

The intricate case of He Jiankui highlights the complex interplay between scientific innovation, ethical boundaries, and national ambitions. While his actions sparked global condemnation, his current status in China underscores a nuanced approach, where the potential for groundbreaking scientific progress may sometimes overshadow past transgressions. This situation invites a deeper reflection on how societies balance scientific advancement with moral responsibilities, and how figures who push the limits of human knowledge are ultimately judged by history.

The Environmental Protection Agency (EPA) has fundamentally altered its method for evaluating air pollution regulations. Historically, the agency quantified the financial benefits associated with improved public health outcomes, such as lives saved and illnesses prevented, due to cleaner air. However, a recent directive signals a departure from this approach, sparking considerable debate and concern among environmental and public health advocates. This policy revision has immediate implications for regulations targeting pollutants like fine particulate matter and ozone, which are known contributors to various adverse health conditions.

For many years, the Environmental Protection Agency has systematically calculated the monetary gains from its environmental statutes, particularly those addressing air quality. These calculations encompassed the economic value of preserving human lives and averting health complications. However, a newly enacted regulation, which relaxes air pollution controls on fossil fuel-powered turbines, indicates a significant shift. The EPA will no longer assign a dollar amount to the health advantages stemming from reduced fine particulate matter and ozone levels. The agency justifies this change by citing the inherent uncertainties in estimating these economic impacts. Brigit Hirsch, the EPA's press secretary, clarified that while health benefits will still be considered, their monetary valuation will be suspended pending a reassessment of the methodology.

This policy adjustment has ignited apprehension among public health experts. Dr. Mary Rice, a pulmonologist and director at Harvard's Center for Climate Health and the Global Environment, expressed worries about the potential ramifications for public well-being. She highlighted the particular vulnerability of individuals with chronic respiratory ailments, children, and the elderly to the detrimental effects of air pollution. Fine particulate matter, often referred to as PM2.5, originates from sources such as power generation facilities and has been linked to a spectrum of serious health issues, including asthma, heart attacks, dementia, and premature mortality. Previous EPA assessments underscored the substantial health and economic benefits of mitigating fine particle pollution, estimating hundreds of thousands of lives saved and billions of dollars in annual savings.

Richard Revesz, an environmental law scholar at NYU, suggests that this shift could pave the way for a broader weakening of air quality regulations. He points out that while the financial burdens on industries for complying with regulations continue to be assessed, the absence of a comparable monetary valuation for health benefits might diminish their perceived importance. This imbalance, he argues, could lead to regulations being rolled back without adequately considering the significant, albeit unquantified, negative consequences for public health. Furthermore, historical data, such as the Harvard Six Cities study, unequivocally demonstrates the direct link between air pollution and reduced life expectancy, with subsequent research consistently reaffirming the health risks associated with fine particle exposure.

The concept of conducting cost-benefit analyses for major regulations, including the Clean Air Act, was mandated by a 1981 executive order. Over time, the EPA developed sophisticated models to quantify the health improvements and associated economic savings from pollution reduction efforts. These analyses frequently demonstrated a high ratio of economic benefits to costs, with some Clean Air Act regulations yielding benefits as high as 30 to 1, according to Dr. Rice. While a 2014 Supreme Court ruling affirmed the necessity for agencies to consider both costs and benefits, it did not prescribe a specific methodology. This legal ambiguity, according to Jeffrey Holmstead, a former EPA official, provides the agency with discretion regarding whether to forgo a direct economic quantification of health benefits, provided that health impacts are still evaluated in some capacity. However, experts like Holmstead acknowledge that a comprehensive cost-benefit analysis typically requires monetizing both aspects, making the EPA's current stance a significant departure from established practice.

Beyond air pollution, the current administration's EPA has initiated similar reconsiderations of economic benefit calculations in other regulatory domains. Examples include proposals to revise vehicle emissions standards, where the agency has reportedly excluded the economic advantages of electric vehicle adoption and significantly lowered estimates for health savings from reduced greenhouse gas emissions. These actions, coupled with attempts to roll back the 2009 endangerment finding concerning greenhouse gases, suggest a broader strategic shift within the EPA. These changes align with stated priorities from EPA administrator Lee Zeldin, who in 2025 articulated a focus on reducing costs for consumers and businesses.

The agency's decision to discontinue the monetary valuation of health benefits in air pollution regulations represents a noteworthy policy reversal. This move could potentially impact the rigor with which future environmental protections are assessed and implemented. Critics contend that by not assigning a dollar value to the public health gains, the agency risks downplaying the societal importance of clean air and could inadvertently facilitate the loosening of environmental safeguards, ultimately affecting the well-being of millions of Americans.